Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances

• US 20030113303A1
• Filed: 10/28/2002
• Published: 06/19/2003
• Est. Priority Date: 02/05/1998
• Status: Abandoned Application

• Current Assignee: Biosense, Inc. (Cardinal Health, Inc.)
• Original Assignee: Biosense, Inc. (Cardinal Health, Inc.)
• Inventors: Schwartz, Yitzhack
• Application Number:
  US10/281,709
• Publication Number:
  US 20030113303A1
• Time in Patent Office: Days
• US Class Current: 424/93.21
• CPC Class Codes: A61B 2017/00022 Sensing or detecting at the treatment site
• CPC Class Codes: A61B 2017/00243 cardiac
• CPC Class Codes: A61B 2017/00247 Making holes in the wall of the heart, e.g. laser Myocardial revascularization
• CPC Class Codes: A61B 2017/22082 after introduction of a substance
• CPC Class Codes: A61B 2018/00392 Transmyocardial revascularisation
• CPC Class Codes: A61B 2034/2051 Electromagnetic tracking systems
• CPC Class Codes: A61B 34/20 Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• CPC Class Codes: A61B 5/06 Devices, other than using radiation, for detecting or locating foreign bodies for removing same A61B17/50 ; determining position of probes within or on the body of the patient
• CPC Class Codes: A61B 5/062 using magnetic field
• CPC Class Codes: A61B 5/283 Invasive
• CPC Class Codes: A61B 5/417 the bone marrow
• CPC Class Codes: A61B 5/7285 for synchronising or triggering a physiological measurement or image acquisition with a physiological event or waveform, e.g. an ECG signal A61B6/5205, A61B6/541, A61B8/5207, A61B8/543 take precedence
• CPC Class Codes: A61K 35/545 Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61M 2025/0076 Unidirectional valves
• CPC Class Codes: A61M 2025/0089 Single injection needle protruding axially, i.e. along the longitudinal axis of the catheter, from the distal tip
• CPC Class Codes: A61M 2025/0166 Sensors, electrodes or the like for guiding the catheter to a target zone, e.g. image guided or magnetically guided
• CPC Class Codes: A61M 2210/125 Heart
• CPC Class Codes: A61M 25/0075 Valve means
• CPC Class Codes: A61M 25/0082 : Catheter tip comprising a tool
• CPC Class Codes: A61M 25/0084 : being one or more injection needles
• CPC Class Codes: A61M 25/0105 : Steering means as part of the catheter or advancing means; Markers for positioning systems for detection of markers A61B
• CPC Class Codes: A61P 21/00 : Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method for inducing vascular growth in tissue of a mammal comprises the steps of delivering a translocation stimulator such as cytokine, chemokine or chemoattractant to a target zone of the tissue and introducing human embryonic stem cells to the mammal for homing the human embryonic stem cells to the target zone of the tissue for effecting vascular growth at the target zone.

Claims

1. A method for inducing vascular growth in tissue of a mammal, the method comprising the steps of:

(a) delivering a translocation stimulator to a target zone of the tissue; and

(b) introducing human embryonic stem cells to the mammal for homing the human embryonic stem cells to the target zone of the tissue for effecting vascular growth at the target zone.

2. The method according to claim 1, further comprising effecting vascular growth by vasculogenesis.

3. The method according to claim 1, further comprising effecting vascular growth by angiogenesis.

4. The method according to claim 1, further comprising effecting vascular growth by arteriogenesis.

5. The method according to claim 1, further comprising genetically engineering human embryonic stem cells to produce a therapeutic protein.

6. The method according to claim 1, further comprising delivering at least one translocation stimulator from the group comprising VEGF, GM-CSF, bFGF, PDGF, IGF-1, PLGF, SDF-1, ANG1, ANG2, TIE2, HGF, TNFα

, TGFβ

, SCGF, Selectin, Integrins, MMP, PECAM, Cadherins, NO, CXC, MCP-1, HIFα

, COX-2 and all isoforms and analogs thereof.

7. The method according to claim 1, further comprising delivering the translocation stimulator to the target zone of the tissue by injection.

8. The method according to claim 7, further comprising using a catheter for the injection of the translocation stimulator.

9. The method according to claim 8, further comprising navigating the catheter to the target zone using a position sensor on the catheter.

10. The method according to claim 8, further comprising injecting the translocation stimulator into the myocardium of the heart.

11. The method according to claim 8, further comprising injecting the translocation stimulator into the epidardium of the heart.

12. The method according to claim 8, further comprising injecting the translocation stimulator within a vessel of the heart.

13. The method according to claim 8, further comprising injecting the translocation stimulator into a wall of a vessel of the heart.

14. The method according to claim 1, further comprising identifying the target zone by mapping the tissue for viability.

15. The method according to claim 14, further comprising mapping the tissue for viability using a catheter having an electrode.

16. The method according to claim 15, further comprising navigating the catheter using a position sensor on the catheter.

17. The method according to claim 1, further comprising introducing the human embryonic stem cells by intravenous administration.

18. The method according to claim 1, further comprising introducing the human embryonic stem cells near the target zone of the tissue.

64. The method according to claim 15, further comprising mapping the tissue for viability in more than one chamber of the heart.

65. The method according to claim 64, further comprising conducting a bi-ventricular mapping procedure.

66. The method according to claim 64, further comprising mapping the tissue using a rapid mapping technique.

67. The method according to claim 66, further comprising creating a viability map using between six to ten points.

68. The method according to claim 67, further comprising creating the viability map with as few as three points.

69. The method according to claim 15, further comprising mapping the tissue using a rapid mapping technique.

70. The method according to claim 69, further comprising creating a viability map using between six to ten points.

71. The method according to claim 70, further comprising creating the viability map with as few as three points.

19. A method for inducing myogenesis in tissue of a mammal, the method comprising the steps of:

(a) delivering a translocation stimulator to a target zone of the tissue; and

(b) introducing human embryonic stem cells to the mammal for homing the human embryonic stem cells to the target zone of the tissue for effecting myogenesis at the target zone.

20. The method according to claim 19, further comprising genetically engineering human embryonic stem cells to produce a therapeutic protein.

21. The method according to claim 19, further comprising delivering at least one translocation stimulator from the group comprising VEGF, GM-CSF, bFGF, PDGF, IGF-1, PLGF, SDF-1, ANG1, ANG2, TIE2, HGF, TNFα

, TGFβ

, SCGF, Selectin, Integrins, MMP, PECAM, Cadherins, NO, CXC, MCP-1, HIFα

, COX-2 and all isoforms and analogs thereof.

22. The method according to claim 19, further comprising delivering the translocation stimulator to the target zone of the tissue by injection.

23. The method according to claim 22, further comprising using a catheter for the injection of the translocation stimulator.

24. The method according to claim 23, further comprising navigating the catheter to the target zone using a position sensor on the catheter.

25. The method according to claim 23, further comprising injecting the translocation stimulator into the myocardium of the heart.

26. The method according to claim 23, further comprising injecting the translocation stimulator into the epicardium of the heart.

27. The method according to claim 23, further comprising injecting the translocation stimulator within a vessel of the heart.

28. The method according to claim 23, further comprising injecting the translocation stimulator into a wall of a vessel of the heart.

29. The method according to claim 19, further comprising identifying the target zone by mapping the tissue for viability.

30. The method according to claim 29, further comprising mapping the tissue for viability using a catheter having an electrode.

31. The method according to claim 30, further comprising navigating the catheter using a position sensor on the catheter.

32. The method according to claim 19, further comprising introducing the human embryonic stem cells by intravenous administration.

33. The method according to claim 19, further comprising introducing the human embryonic stem cells near the target zone of the tissue.

72. The method according to claim 30, further comprising mapping the tissue for viability in more than one chamber of the heart.

73. The method according to claim 72, further comprising conducting a bi-ventricular mapping procedure.

74. The method according to claim 72, further comprising mapping the tissue using a rapid mapping technique.

75. The method according to claim 74, further comprising creating a viability map using between six to ten points.

76. The method according to claim 75, further comprising creating the viability map with as few as three points.

77. The method according to claim 30, further comprising mapping the tissue using a rapid mapping technique.

78. The method according to claim 77, further comprising creating a viability map using between six to ten points.

79. The method according to claim 78, further comprising creating the viability map with as few as three points.

34. A method for inducing remodeling in tissue of a mammal, the method comprising the steps of:

(a) delivering a translocation stimulator to a target zone of the tissue; and

(b) introducing human embryonic stem cells to the mammal for homing the human embryonic stem cells to the target zone of the tissue for effecting remodeling of the tissue at the target zone.

35. The method according to claim 34, further comprising genetically engineering human embryonic stem cells to produce a therapeutic protein.

36. The method according to claim 34, further comprising delivering at least one translocation stimulator from the group comprising VEGF, GM-CSF, bFGF, PDGF, IGF-1, PLGF, SDF-1, ANG1, ANG2, TIE2, HGF, TNFα

, TGFβ

, SCGF, Selectin, Integrins, MMP, PECAM, Cadherins, NO, CXC, MCP-1, HIFα

, COX-2 and all isoforms and analogs thereof.

37. The method according to claim 34, further comprising delivering the translocation stimulator to the target zone of the tissue by injection.

38. The method according to claim 37, further comprising using a catheter for the injection of the translocation stimulator.

39. The method according to claim 38, further comprising navigating the catheter to the target zone using a position sensor on the catheter.

40. The method according to claim 38, further comprising injecting the translocation stimulator into the myocardium of the heart.

41. The method according to claim 38, further comprising injecting the translocation stimulator into the epidardium of the heart.

42. The method according to claim 38, further comprising injecting the translocation stimulator within a vessel of the heart.

43. The method according to claim 38, further comprising injecting the translocation stimulator into a wall of a vessel of the heart.

44. The method according to claim 34, further comprising identifying the target zone by mapping the tissue for viability.

45. The method according to claim 44, further comprising mapping the tissue for viability using a catheter having an electrode.

46. The method according to claim 45, further comprising navigating the catheter using a position sensor on the catheter.

47. The method according to claim 34, further comprising introducing the human embryonic stem cells by intravenous administration.

48. The method according to claim 34, further comprising introducing the human embryonic stem cells near the target zone of the tissue.

80. The method according to claim 45, further comprising mapping the tissue for viability in more than one chamber of the heart.

81. The method according to claim 80, further comprising conducting a bi-ventricular mapping procedure.

82. The method according to claim 80, further comprising mapping the tissue using a rapid mapping technique.

83. The method according to claim 82, further comprising creating a viability map using between six to ten points.

84. The method according to claim 83, further comprising creating the viability map with as few as three points.

85. The method according to claim 45, further comprising mapping the tissue using a rapid mapping technique.

86. The method according to claim 85, further comprising creating a viability map using between six to ten points.

87. The method according to claim 86, further comprising creating the viability map with as few as three points.

49. A method for replacing a scar in tissue of a mammal, the method comprising the steps of:

(a) establishing the scar as a target zone;

(b) delivering a translocation stimulator to the target zone of the tissue; and

(c) introducing human embryonic stem cells to the mammal for homing the human embryonic stem cells to the target zone of the tissue for effecting replacement of the scar at the target zone.

50. The method according to claim 49, further comprising genetically engineering human embryonic stem cells to produce a therapeutic protein.

51. The method according to claim 49, further comprising delivering at least one translocation stimulator from the group comprising VEGF, GM-CSF, bFGF, PDGF, IGF-1, PLGF, SDF-1, ANG1, ANG2, TIE2, HGF, TNFα

, TGFβ

, SCGF, Selectin, Integrins, MMP, PECAM, Cadherins, NO, CXC, MCP-1, HIFα

, COX-2 and all isoforms and analogs thereof.

52. The method according to claim 49, further comprising delivering the translocation stimulator to the target zone of the tissue by injection.

53. The method according to claim 52, further comprising using a catheter for the injection of the translocation stimulator.

54. The method according to claim 53, further comprising navigating the catheter to the target zone using a position sensor on the catheter.

55. The method according to claim 53, further comprising injecting the translocation stimulator into the myocardium of the heart.

56. The method according to claim 53, further comprising injecting the translocation stimulator into the epidardium of the heart.

57. The method according to claim 53, further comprising injecting the translocation stimulator within a vessel of the heart.

58. The method according to claim 53, further comprising injecting the translocation stimulator into a wall of a vessel of the heart.

59. The method according to claim 49, further comprising identifying the target zone by mapping the tissue for viability.

60. The method according to claim 59, further comprising mapping the tissue for viability using a catheter having an electrode.

61. The method according to claim 60, further comprising navigating the catheter using a position sensor on the catheter.

62. The method according to claim 49, further comprising introducing the human embryonic stem cells by intravenous administration.

63. The method according to claim 49, further comprising introducing the human embryonic stem cells near the target zone of the tissue.

88. The method according to claim 60, further comprising mapping the tissue for viability in more than one chamber of the heart.

89. The method according to claim 88, further comprising conducting a bi-ventricular mapping procedure.

90. The method according to claim 89, further comprising mapping the tissue using a rapid mapping technique.

91. The method according to claim 90, further comprising creating a viability map using between six to ten points.

92. The method according to claim 91, further comprising creating the viability map with as few as three points.

93. The method according to claim 60, further comprising mapping the tissue using a rapid mapping technique.

94. The method according to claim 93, further comprising creating a viability map using between six to ten points.

95. The method according to claim 94 further comprising creating the viability map with as few as three points.